CellarisBio Delivers Real-Time Cell Target Engagement System for Challenging Drug Targets
CellarisBio Delivers Real-Time Cell Target Engagement System for Challenging Drug Targets
PR Newswire
SAN DIEGO, Oct. 1, 2024
SAN DIEGO, Oct. 1, 2024 /PRNewswire/ -- CellarisBio releases its real-time cell target engagement application for its MICRO-TAG™ platform. This new scalable application adds to the robustness of the MICRO-TAG™ platform and marks a new level in the cell target engagement space. The application seamlessly integrates with real-time instruments, such as Applied Biosystems' QuantStudio™, BIO-RAD's CFX96™ and QIAGEN's QIAquant™ systems.
Elmar Nurmemmedov, CellarisBio cofounder and CEO, said: "This marks a new era in drug discovery for challenging drug targets - these are the type of targets known to the drug discovery industry as "undruggable". By interrogating potential targets directly within the complex proteomic environment of the cell in real time, we not only enable sensitive discovery and validation of potent therapeutic candidates, but also add valuable mechanistic insight into precision therapeutic targeting."
Real-time cell target engagement enables simultaneous biological and biophysical evaluation of therapeutic candidates for direct engagement with its intended target within live cells. "We are excited to be at the forefront of novel technologies for drug discovery. Our new real-time system will help de-risk and accelerate first-in-class drug discovery programs. Degraders, molecular glues and covalent inhibitors are several of the therapeutic modalities that will be within our range of impact," added Ivan Babic, CellarisBio cofounder and CSO.
CellarisBio's MICRO-TAG™ platform offers a real-time solution for precision therapeutic discovery in the cell. The utility of real-time instruments as part of this platform provides a streamlined workflow, increased sensitivity and wider dynamic range. "CellarisBio aims to empower the drug discovery community to discover life-saving therapies of the future" noted Elmar Nurmemmedov.
Watch the official CellarisBio trailer here: Youtube
Download white paper: CellarisBio
About CellarisBio
CellarisBio is a drug discovery company, developing the next-gen cell target engagement technology, delivered as MICRO-TAG™ platform. Located at prestigious Biovista labs, CellarisBio is an established player in San Diego's biotech community. The company capitalizes on several patents protecting the technology. For more information, please visit www.cellarisbio.com.
Contact:
hi@cellarisbio.com
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks
-
Real Estate: Performance Continues to Be Driven by Interest-Rate Movements
-
Financial Services: Sector Doing Well Heading Into Rate-Cutting Cycle
-
Energy: OPEC Faces Hard Supply Decision in Latter Half of 2024
-
This Cheap Stock Is Still a Buy Even After 50% Rally
-
10 Top-Performing Dividend Stocks of Q3 2024
United States